लोड हो रहा है…
Adjuvant FOLFIRINOX in Patients with Resectable Pancreatic Cancer Is Effective but Rarely Feasible in Real Life: Is Neoadjuvant FOLFIRINOX a Better Option?
SIMPLE SUMMARY: In this paper, we showed that only a minority of patients (23%) undergoing upfront pancreatic resection completed the planned 12 courses of FOLFIRINOX, and we delineated the reasons for not completing it. We showed that patients who received neoadjuvant treatment were significantly m...
| मुख्य लेखकों: | , , , , , , , , , |
|---|---|
| स्वरूप: | Online लेख मूलपाठ |
| भाषा: | English |
| प्रकाशित: |
MDPI
2023
|
| विषय: | |
| ऑनलाइन पहुंच: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10252647/ https://www.ncbi.nlm.nih.gov/pubmed/37297011 http://dx.doi.org/10.3390/cancers15113049 |